Skip to main content
Signal8

Surgery Partners, Inc. (SGRY) Form 10-Q — Nov 9, 2026

$SGRYForm 10-QFiled Nov 9, 2026, 5:14 PM ET0001638833-26-000090Original filing

Surgery Partners filed its Q3 2026 10-Q showing revenue of $815.3 million, down 0.8% year over year, with a net loss attributable to the company of $21.1 million ($0.16 per share). Days adjusted same-facility revenues grew 6.0%, driven by a 5.8% increase in revenue per case, but Adjusted EBITDA slipped 2.7% to $132.7 million. The dominant disclosure is the pending take-private merger: Spyglass Topco will acquire SGRY for $25.00 per share in cash under a merger agreement amended November 8, 2026, which added a 10% per annum ticking fee (max $1.61 per share) if closing slips past March 1, 2027. Upon closing, SGRY common stock will be delisted from Nasdaq.

Key figures

Revenue
815.3
Revenue Yoy
-0.8%
Cash Position
354.5
Deal Value Usd
approximately $796.6 million (Idaho Transaction consideration)
Shares Outstanding
130881223
Termination fee
149.1
Ticking fee rate
10% per annum
Revolver capacity
692.8
Interest expense q3
67.9
Merger outside date
October 23, 2027
Surgical facilities
173
Term loan prepayment
285
Merger per share price
25
Adjusted ebitda q3 2025
136.4
Adjusted ebitda q3 2026
132.7
Operating cash flow ytd
174.5
Adjusted ebitda ytd 2026
360.2
Expense reimbursement cap
8.25
Max ticking fee per share
1.61
Same facility case growth q3
0.2%
Same facility revenue growth q3
6.0%
Same facility revenue per case growth q3
5.8%

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Surgery Partners, Inc. (SGRY) Form 10-Q — Nov 9, 2026: AI Analysis | Signal8